Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ring finger protein 144A (RNF144A)
- Target
- RNF144A
- Molecular classification
- E3 ubiquitin ligase, RING-between-RING (RBR) family protein
01
Overview
Ring finger protein 144A (RNF144A) is an E3 ubiquitin ligase belonging to the RING-between-RING (RBR) family of ubiquitin ligases, characterized by its ability to catalyze ubiquitin linkages and target specific proteins for proteasomal degradation, including DNA repair and heat shock proteins. It acts as a tumor suppressor, especially in breast cancer, by promoting degradation of oncoproteins such as HSPA2 and DNA repair factors like PARP1 and DNA-PKcs. Its expression is responsive to DNA damage and loss of RNF144A function is associated with increased tumor growth, poor cancer prognosis, and may influence sensitivity to drugs such as PARP inhibitors. RNF144A may also function in innate immunity via regulation of the STING pathway.
- Other names
- RNF144ARNF144UBCE7IP4hUIP4UIP4ring finger protein 144A
02
Mechanism of action
Promotes ubiquitination and proteasomal degradation of specific substrates (DNA-PKcs, PARP1, HSPA2, RAF1, BMI1); Alters sensitivity to PARP inhibitors by modulating PARP1 protein abundance
03
Biological functions
Ubiquitination (catalyzes transfer of ubiquitin to substrates)Protein degradation (targets proteins for proteasomal degradation)Regulation of DNA repairModulation of apoptosis (promotes apoptosis following DNA damage)Innate immune response regulation (mediates STING1 ubiquitination)
04
Disease associations
Cancer (tumor suppressor function, especially in breast cancer)Neurological disease (related to RBR family; e.g., parkin in Parkinson disease)
05
Safety considerations
Limited direct therapeutic targeting; disruption could impair DNA repair, promote tumor progression, or alter cell death pathways
06
Interacting drugs
PARP inhibitors (e.g. olaparib; indirectly, via regulation of PARP1 levels)
07
Biomarkers
Low RNF144A expression correlates with aggressive breast cancer and poor prognosis; can predict PARP inhibitor sensitivity in breast cancer
Beyond the preview
Go deeper on Ring finger protein 144A (RNF144A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ring finger protein 144A (RNF144A).